Neutralization of ARCoV-induced sera against SARS-CoV-2 variants

• मुख्य लेखकों: Xiao-Feng Li (लेखक), Na-Na Zhang (लेखक), Yu-Hua Li (लेखक), Shou-Chun Cao (लेखक), Yi-Fei Zhang (लेखक), Cheng-Feng Qin (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Taylor & Francis Group, 2022-11-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

ARCoV is a candidate mRNA vaccine encoding receptor-binding domain of SARS-CoV-2. Its safety, tolerability, and immunogenicity profile have been confirmed in the phase 1 clinical trial in China. A multi-regional phase 3 clinical trial is currently underway to test the efficacy of ARCoV (NCT04847102)...